These are the posts from the How we think section that have been tagged with HCP.
To see all tags used in our posts, click here.
| 4th September 2017
The market is noisy with technological advancements presenting opportunities of all shapes and sizes. But where should pharma invest to remain at the forefront of healthcare into the future? Account Director Dolan Desai investigates the prospects for new health technologies.
| 23rd March 2017
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of the healthcare professional (HCP) in the patient journey? Associate Consultant Ditte Funding discusses challenges and opportunities.
| 8th February 2017
When we talk about customers as experts in healthcare, what we’re really talking about are clinicians. Experts in diagnosis, treatment and clinical care (HCPs) and experts as those who experience the medical condition in their own personal context (patients). Head of Customer Experience Elisa del Galdo talks through how the evolution of the relationship between HCPs and patients is changing the role of the expert in healthcare.
| 25th January 2017
Simon Young, Director at Blue Latitude Health, discusses how advances in technology are influencing the future of the expert-patient relationship and why healthcare businesses must evaluate how best to support the future role of the expert.
| 9th January 2017
In the 2017 trends edition of Perspective magazine, we explore how advances in technology are influencing the future of the expert-patient relationship and the role healthcare businesses can take in supporting and enhancing these interactions at the point of need.
| 18th August 2016
What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment? Even more importantly, what do immunotherapies mean for patients who face diagnosis of advanced cancers? Senior Associate Consultants Frances Hendry and Zoe Bartley tackle these complex questions.
| 3rd August 2016
In this article, Consultant Jeremy Poland examines some of the key dynamics in prostate cancer multi-disciplinary teams across Europe and how the recent trends impact the opportunities available to healthcare marketers.
| 13th June 2016
In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities of Britain exiting the EU (Brexit).
| 19th May 2016
Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology.